RAPT Therapeutics, Inc. (RAPT) Enterprise Value (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Enterprise Value for 5 consecutive years, with -$97.9 million as the latest value for Q3 2024.
- Quarterly Enterprise Value rose 47.01% to -$97.9 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was -$97.9 million through Sep 2024, up 47.01% year-over-year, with the annual reading at -$158.8 million for FY2023, 36.25% up from the prior year.
- Enterprise Value hit -$97.9 million in Q3 2024 for RAPT Therapeutics, up from -$114.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$97.9 million in Q3 2024 to a low of -$249.1 million in Q4 2022.
- Historically, Enterprise Value has averaged -$167.7 million across 5 years, with a median of -$173.0 million in 2022.
- Biggest five-year swings in Enterprise Value: crashed 75.81% in 2022 and later soared 47.01% in 2024.
- Year by year, Enterprise Value stood at -$111.5 million in 2020, then tumbled by 70.08% to -$189.7 million in 2021, then plummeted by 31.33% to -$249.1 million in 2022, then soared by 36.25% to -$158.8 million in 2023, then skyrocketed by 38.34% to -$97.9 million in 2024.
- Business Quant data shows Enterprise Value for RAPT at -$97.9 million in Q3 2024, -$114.8 million in Q2 2024, and -$141.6 million in Q1 2024.